Vir Biotechnology, Inc. (VIR)
| Market Cap | 3.05B |
| Revenue (ttm) | 1.62B |
| Net Income (ttm) | 515.84M |
| Shares Out | 133.53M |
| EPS (ttm) | 3.83 |
| PE Ratio | 5.93 |
| Forward PE | 4.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 434,135 |
| Open | 22.77 |
| Previous Close | 22.72 |
| Day's Range | 22.60 - 23.01 |
| 52-Week Range | 18.05 - 31.78 |
| Beta | 0.26 |
| Analysts | Buy |
| Price Target | 51.15 (+123.8%) |
| Earnings Date | May 4, 2023 |
About VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of He... [Read more]
Financial Performance
In 2022, VIR's revenue was $1.62 billion, an increase of 47.51% compared to the previous year's $1.10 billion. Earnings were $515.84 million, a decrease of -2.41%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for VIR stock is "Buy." The 12-month stock price forecast is $51.15, which is an increase of 123.80% from the latest price.
News
Is the Options Market Predicting a Spike in Vir Biotechnology (VIR) Stock?
Investors need to pay close attention to Vir Biotechnology (VIR) stock based on the movements in the options market lately.
SVB fall casts shadow on early-stage U.S. biotech
The collapse of Silicon Valley Bank will leave early-stage biotechnology companies with a funding void, investors and analysts said on Monday, but larger, publicly-traded drug companies should escape ...
Vir Biotechnology to Participate in the Barclays Global Healthcare Conference
SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of...
Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
SAN FRANCISCO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will parti...
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Misses Revenue Estimates
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -1,800% and 80.07%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st...
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact –
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK's National Institute for Health and Care Excellence (NICE)
Final draft guidance based on cost effectiveness evaluation of sotrovimab Final draft guidance based on cost effectiveness evaluation of sotrovimab
This biotech stock could double from here: Goldman Sachs
Vir Biotechnology Inc (NASDAQ: VIR) jumped nearly 10% this morning after a Goldman Sachs analyst turned super bullish on the clinical-stage immunology company.
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter a...
Vir Biotechnology, Inc. (VIR) Expected to Beat Earnings Estimates: Should You Buy?
Vir Biotechnology, Inc. (VIR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer
– Experienced biotech executive brings more than 20 years of financial leadership to Vir –
Vir Biotechnology Announces Amended Collaboration Agreement with GSK
– Vir to continue advancing next-generation COVID-19 solutions independently or with other partners –
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edg...
7 Healthcare Stocks That Will Be Big Winners in 2023
Healthcare stocks performed well in 2022, driven by a number of factors. One of the main drivers was the ongoing COVID-19 pandemic, which continued to boost demand for healthcare products and services...
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D.
– Dr. De Backer to assume CEO role on April 3, 2023 –
Vir Biotechnology, Inc. (VIR) Moves to Strong Buy: Rationale Behind the Upgrade
Vir Biotechnology, Inc. (VIR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?
Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference
– Critical Phase 2 readouts anticipated in 2023 for three advanced programs – hepatitis B, hepatitis D and influenza –
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
Should Value Investors Buy Vir Biotechnology (VIR) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...
Vir Biotechnology: A 'Magic Formula' Top Performer
Joel Greenblatt (Trades, Portfolio), the manager of Gotham Capital, has what he calls a “Magic Formula” for investing. First detailed in "The Little Book That Beats the Market," this formula is based ...
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
– Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 – – Approximately 3,000 participants enrolled with initial trial data expected in mid-2023 –
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 71%: Here's is How to Trade
The consensus price target hints at a 70.9% upside potential for Vir Biotechnology, Inc. (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear...
5 Winning Stocks Backed by the Overlooked Rising P/E Trick
Want to try an out-of-the-box approach? Tap AMC Entertainment (AMC), Live Nation Entertainment (LYV), CuriosityStream (CURI), Helius Medical Technologies (HSDT) and Vir Biotechnology (VIR).